Literature DB >> 10089101

A novel assay for detecting antibodies to cytochrome P4502D6, the molecular target of liver kidney microsomal antibody type 1.

N Kerkar1, Y Ma, M Hussain, L Muratori, C Targett, R Williams, F B Bianchi, G Mieli-Vergani, D Vergani.   

Abstract

Liver Kidney Microsomal type 1 (LKM1) antibody, the diagnostic marker of autoimmune hepatitis type 2, is also found in a proportion of patients with hepatitis C virus infection (HCV). It is detected conventionally by the subjective immunofluorescence technique. Our aim was to establish a simple and objective enzyme-linked immunosorbent assay (ELISA) that measures antibodies to cytochrome P4502D6 (CYP2D6), the target of LKM1. An indirect ELISA using eukaryotically expressed CYP2D6 was designed. Absorbance values obtained against a reference microsomal preparation were subtracted from those obtained against a microsomal preparation over-expressing CYP2D6, thus removing the non-CYP2D6-specific reaction. Sera from 51 LKM1 positive patients (21 autoimmune hepatitis and 30 with HCV infection), 111 LKM1 negative patients with chronic liver disease (including 20 with HCV infection) and 43 healthy controls were tested. Of 51 patients positive by immunofluorescence, 48 were also positive by ELISA while all the 154 LKM1 negative subjects were also negative by ELISA. There was a high degree of association between IFL and ELISA as demonstrated by a kappa reliability value of 0.96. The absorbance values by ELISA correlated with immunofluorescence LKM1 titres both in autoimmune hepatitis (r = 0.74, p < 0.001) and HCV infection (r = 0.67, p < 0.001). The simple, objective ELISA described has the potential to replace the standard immunofluorescence technique.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10089101     DOI: 10.1016/s0022-1759(98)00213-0

Source DB:  PubMed          Journal:  J Immunol Methods        ISSN: 0022-1759            Impact factor:   2.303


  3 in total

1.  Detection of liver kidney microsomal type 1 antibody using molecularly based immunoassays.

Authors:  N Kerkar; Y Ma; E T Davies; P Cheeseman; G Mieli-Vergani; D Vergani
Journal:  J Clin Pathol       Date:  2002-12       Impact factor: 3.411

2.  Anti-Tribbles homolog 2 autoantibodies in Japanese patients with narcolepsy.

Authors:  Hiromi Toyoda; Susumu Tanaka; Taku Miyagawa; Yutaka Honda; Katsushi Tokunaga; Makoto Honda
Journal:  Sleep       Date:  2010-07       Impact factor: 5.849

3.  Anti-Tribbles homolog 2 (TRIB2) autoantibodies in narcolepsy are associated with recent onset of cataplexy.

Authors:  Minae Kawashima; Ling Lin; Susumu Tanaka; Poul Jennum; Stine Knudsen; Sona Nevsimalova; Giuseppe Plazzi; Emmanuel Mignot
Journal:  Sleep       Date:  2010-07       Impact factor: 5.849

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.